- 全部删除
您的购物车当前为空
KIF18A-IN-6(Compound 134)是一种具有口服活性的KIF18A抑制剂,抑制KIF18A微管依赖性ATPase活性,IC50为0.016 μM,能够在小鼠模型中降低HCC15肿瘤体积,可用于研究KIF18A相关癌症。


为众多的药物研发团队赋能,
让新药发现更简单!
KIF18A-IN-6(Compound 134)是一种具有口服活性的KIF18A抑制剂,抑制KIF18A微管依赖性ATPase活性,IC50为0.016 μM,能够在小鼠模型中降低HCC15肿瘤体积,可用于研究KIF18A相关癌症。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 413 | In stock | |
| 5 mg | ¥ 828 | In stock | |
| 10 mg | ¥ 1,320 | In stock | |
| 25 mg | ¥ 2,190 | In stock | |
| 50 mg | ¥ 3,490 | In stock | |
| 100 mg | ¥ 5,670 | In stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 987 | In stock |
KIF18A-IN-6 相关产品
| 产品描述 | KIF18A-IN-6 (Compound 134) is an orally active KIF18A inhibitor that suppresses KIF18A microtubule-dependent ATPase activity with an IC50 of 0.016 μM. It reduces HCC15 tumour volume in mouse models and may be employed in KIF18A-associated cancer research. |
| 靶点活性 | KIF18A microtubule-dependent ATPase activity:0.016 μM |
| 体外活性 | KIF18A-IN-6 显示出对 JIMT-1、HCC-15 和 NIH-OVCAR3 细胞的活力抑制作用,其对应的 IC50 值分别为IC50 分别为 0.0040、0.0051 和 0.0051 μM。[1] |
| 体内活性 | KIF18A-IN-6 (10-60 mg/kg,每日一次或两次,持续1个月) 通过口服给药,有效抑制了小鼠体内HCC15和OVCAR3肿瘤的生长。[1] |
| 分子量 | 559.74 |
| 分子式 | C28H37N3O5S2 |
| CAS No. | 2914879-10-8 |
| 颜色 | Yellow |
| 物理性状 | Solid |
| 存储 | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 100 mg/mL (178.65 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
评论内容